Forest Laboratories

Forest Laboratories CEO Howard Soloman to retire

Friday, May 24, 2013 10:02 AM

Forest Laboratories, an international pharmaceutical company, announced that Howard Solomon will retire as chief executive officer and president, effective December 31, 2013. Solomon has served as CEO since 1977, chairman since 1998 and president since 2010.

More... »

Trevena, Forest Labs to develop TRV027 for acute heart failure

Thursday, May 9, 2013 11:16 AM

Trevena, a clinical stage pharmaceutical company focused on G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories, a global pharmaceutical company, have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed phase IIa clinical trials. Trevena expects to commence a 500-patient multi-center phase IIb clinical trial in acute decompensated heart failure (ADHF) by year end.

More... »

Jeff Jonas joins Shire leadership team

Tuesday, November 20, 2012 11:51 AM

Irish specialty biopharmaceutical company Shire has appointed Jeff Jonas, MD, as president of Shire's regenerative medicine business.

More... »

Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer's

Wednesday, November 14, 2012 02:45 PM

Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer's type in the U.S.

More... »

Forest Laboratories, moksha8 form strategic alliance for Latin America

Wednesday, October 24, 2012 10:33 AM

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

More... »

Forest Labs and Nabriva to develop novel antibacterial agent

Friday, June 1, 2012 10:43 AM

Forest Laboratories, an international pharmaceutical manufacturer and marketer, and biotech Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781.

More... »

The CenterWatch Monthly, June 2012

Friday, June 1, 2012 09:00 AM

Western Europe sees drop in active investigators

More... »

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

More... »

Rosenberg joins Esperion Therapeutics as CMO

Monday, April 9, 2012 02:56 PM

Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.

More... »

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

More... »